Isracann Biosciences Price To Sales vs. Number Of Employees
Based on Isracann Biosciences' profitability indicators, Isracann Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Isracann Biosciences' ability to earn profits and add value for shareholders.
Check out Risk vs Return Analysis.
For Isracann Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Isracann Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Isracann Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Isracann Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Isracann Biosciences over time as well as its relative position and ranking within its peers.
Isracann |
Isracann Biosciences Number Of Employees vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Isracann Biosciences's current stock value. Our valuation model uses many indicators to compare Isracann Biosciences value to that of its competitors to determine the firm's financial worth. Isracann Biosciences is rated third overall in price to sales category among its peers. It is rated below average in number of employees category among its peers creating about 0.45 of Number Of Employees per Price To Sales. The ratio of Price To Sales to Number Of Employees for Isracann Biosciences is roughly 2.21 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Isracann Biosciences' earnings, one of the primary drivers of an investment's value.Isracann Number Of Employees vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Isracann Biosciences |
| = | 8.83 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Isracann Biosciences |
| = | 4 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Isracann Number Of Employees vs Competition
Isracann Biosciences is rated below average in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 18,066. Isracann Biosciences adds roughly 4.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Isracann Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Isracann Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Isracann Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Isracann Biosciences' change in net profit over the period of time. It can combine multiple indicators of Isracann Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. Isracann Biosciences is traded on OTC Exchange in the United States.
Isracann Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Isracann Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Isracann Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Isracann Biosciences' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Isracann Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Use Investing Themes to Complement your Isracann Biosciences position
In addition to having Isracann Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electronics Thematic Idea Now
Electronics
Companies manufacturing electronic appliances and goods. The Electronics theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronics Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Isracann Pink Sheet
To fully project Isracann Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Isracann Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Isracann Biosciences' income statement, its balance sheet, and the statement of cash flows.